Arcutis files proposed sale of 6,287 shares

Arcutis Biotherapeutics proposes the sale of 6,287 common shares following restricted stock vesting on 03/01/2026.

Rhea-AI Filing Summary

Arcutis Biotherapeutics proposes the sale of 6,287 common shares following restricted stock vesting on 03/01/2026. The filing lists recent open‑market sales by reporting person Patrick Burnett, including 11,500 shares on 12/15/2025 and 9,794 shares on 02/04/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ARQT disclose in the Form 144?

The Form 144 discloses a proposed sale of 6,287 common shares tied to restricted stock vesting on 03/01/2026. It also lists multiple recent sales by the reporting person with dates and share counts disclosed in the filing.

Who is the reporting person named in ARQT's filing?

The filing names Patrick Burnett as the reporting person. The document provides his address and multiple recent sale entries, identifying him as the source of the disclosed past sales and the proposed sale linked to restricted stock vesting.

Which recent sales by the insider are listed in the filing?

The filing shows recent sales including 11,500 shares on 12/15/2025, 9,794 shares on 02/04/2026, and 3,675 shares on 02/02/2026, with dollar amounts reported alongside each transaction.

What is the transaction trigger for the proposed sale in ARQT's Form 144?

The proposed sale of 6,287 common shares is tied to restricted stock vesting on 03/01/2026, as stated in the filing. The filing links the shares to vesting rather than to an open‑market purchase.

On which exchange are the shares listed according to the filing?

The filing lists the securities as common shares traded on NASDAQ. The exchange designation appears alongside the security details and the proposed sale information in the Form 144 excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 06:21 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001741987
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Patrick Burnett
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	6287	158319.86	122492192	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			6287	03/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	02/04/2026	9794	252748.08
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	02/02/2026	3675	93706.62
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	01/05/2026	2490	72165.7
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	12/31/2025	1697	49561.25
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	12/15/2025	11500	332851.03

144: Remarks and Signature

Remarks
Date of Notice	03/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Patrick Burnett
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)